Human CCL7/MCP-3/MARC Antibody, R&D Systems™

CCL7/MCP-3/MARC

Polyclonal

Unconjugated

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative

C-C motif chemokine 7, chemokine (C-C motif) ligand 7, FIC, MARC, MCP-3, MCP3Monocyte chemotactic protein 3, MCP-3Small-inducible cytokine A7, MGC138465, Monocyte chemoattractant protein 3, NC28SCYA6, SCYA7MGC138463, small inducible cytokine A7 (monocyte chemotactic protein 3)

Goat

Affinity Purified

RUO

6354

Reconstitute at 0.2 mg/mL in sterile PBS.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

Western Blot, Neutralization

LYOPH

Western Blot 0.1 ug/mL, Neutralization 10-30 ug/mL

Q7Z7Q8

CCL7

E. coli-derived recombinant human CCL7/MCP-3/MARC (R&D Systems, Catalog # 282-P3) Gln34-Leu109 Accession # Q7Z7Q8

25 μg

Primary

Detects human CCL7/MCP-3/MARC in direct ELISAs and Western blots. In these formats, less than 20% cross-reactivity with recombinant human (rh) Eotaxin is observed and less than 5% cross-reactivity with rhMCP-2, rhMCP-1, and recombinant mouse JE is observed.

Human

IgG